MAP2K7 and non-small cell lung carcinoma: Bi-therapies involving osimertinib and MEK TKI have shown antitumor activity in clinical case studies of EGFR-mutant NSCLC patients (Dagogo-Jack et al, 2019; Xie et al, 2021), and some clinical trials are in progress to evaluate the efficacy of the osimertinib/selumetinib (MEK inhibitor) combo (NCT03944772, NCT03392246).